Table 1.

Summary of recent active clinical trials using cellular immunotherapy against breast cancer as a monotherapy or in combination approaches with checkpoint inhibitors or chemotherapy. Clinicaltrials.gov, accessed March 2022, search terms used were “cellular immunotherapy” and” breast cancer”, with the search criteria focusing on recently added studies in early phases using cellular immunotherapy against breast cancer excluding vaccination approaches.

Study Title	NCT	Interventions	Cell Target	Phase
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases	NCT03696030 [97]	Biological: Chimeric Antigen Receptor T-Cell Therapy	HER2	Phase 1; Recruiting
Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)	NCT04020575 [98]	Biological: huMNC2-CAR44 CAR T cells Biological: huMNC2-CAR44 CAR T cells @ RP2D	MUC1	Phase 1; Recruiting
EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer	NCT02915445 [99]	Biological: CAR-T cells recognizing EpCAM	EpCAM	Phase 1; Recruiting
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer	NCT04639245 [88]	Biological: MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells Biological: PD1 Inhibitor Drug: Atezolizumab Drug: Fludarabine Drug: Cyclophosphamide	MAGE-A1	Phase 1/2; Recruiting
T-Cell Therapy for Advanced Breast Cancer	NCT02792114 [100]	Biological: Mesothelin-targeted T cells Drug: Cyclophosphamide Drug: AP1903	Mesothelin	Phase 1; Active, not recruiting
BATs in Patients With Breast Cancer and Leptomeningeal Metastases	NCT03661424 [101]	Drug: HER2 BATs	n.a	Phase 1; Recruiting
RAPA-201 Therapy of Solid Tumors	NCT05144698 [90]	Biological: RAPA-201 Rapamycin Resistant T Cells Drug: Chemotherapy Prior to RAPA-201 Therapy	n.a	Phase 2; Recruiting
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)	NCT03682744 [102]	Biological: anti-CEA CAR-T cells	CEA	Phase 1; Active, not recruiting
Her2-BATS and Pembrolizumab in Metastatic Breast Cancer	NCT03272334 [91]	Drug: HER2 BATs with Pembrolizumab	HER2	Phase 1/2; Recruiting
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin	NCT02414269 [89]	Genetic: iCasp9M28z T cell infusions Drug: Cyclophosphamide Drug: Pembrolizumab	Mesothelin	Phase 1/2; Active, not recruiting
A Study to Investigate LYL797 in Adults With Solid Tumors	NCT05274451 [103]	Biological: LYL797	ROR1	Phase 1; Not yet recruiting
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)	NCT03635632 [92]	Genetic: C7R-GD2.CART cells Drug: Cyclophosphamide Drug: Fludarabine	GD2	Phase 1; Recruiting
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors	NCT03970382 [93]	Biological: NeoTCR-P1 adoptive cell therapy Biological: Nivolumab Biological: IL-2	neoepitope (neoE)	Phase 1; Active, not recruiting
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors	NCT03841110 [94]	Drug: FT500 Drug: Nivolumab Drug: Pembrolizumab Drug: Atezolizumab Drug: Cyclophosphamide Drug: Fludarabine Drug: IL-2	n.a	Phase 1; Recruiting
Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer	NCT02491697 [104]	Biological: DC-CIK Immunotherapy Drug: Capecitabine Monotherapy and Combination	n.a	Phase 2; Active, not recruiting
A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors	NCT04476641 [95]	Other: CELL	n.a	Phase 2; Recruiting
Immunotherapy Using Tumor-infiltrating Lymphocytes for Patients With Metastatic Cancer	NCT01174121 [96]	Biological: Young TIL Drug: Aldesleukin Drug: Cyclophosphamide Drug: Fludarabine Drug: Pembrolizumab	n.a	Phase 2; Recruiting